Omnicell, Inc.

Omnicell Announces Third Quarter 2026 Financial Results

Omnicell delivered Q3 2026 revenue of $308 million, down 1% year-over-year, but revenue and profitability both exceeded the high end of prior guidance. GAAP EPS doubled to $0.24 from $0.12 a year ago, while non-GAAP EPS rose to $0.58 from $0.51 and non-GAAP EBITDA reached $45 million on margin expansion and cost discipline. The company raised full-year 2026 non-GAAP EBITDA guidance to $187M-$193M and non-GAAP EPS to $2.48-$2.56, tightened revenue and ARR ranges, and reiterated product bookings guidance of $425M-$560M. Management highlighted momentum in the next-generation Titan XT plus OmniSphere cloud platform as the core long-term growth driver in autonomous medication management.

•10d ago

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

TraceLink and Omnicell have integrated TraceLink's Drug Supply Chain Security Act (DSCSA) compliance solution into Omnicell's central pharmacy inventory management workflows, embedding serialized product verification and traceability directly into hospital medication receiving. Pharmacy teams using Omnicell Central Pharmacy Manager can now verify serialized medicines, resolve verification exceptions, and complete compliance reporting inside their existing workflows, replacing separate compliance tools and manual processes. For Omnicell, the deal expands the range of DSCSA integration options available to its central pharmacy customers; no financial terms were disclosed, making this an incremental product enhancement rather than a material event.

•2mo ago

EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 · Designed to Help Pharmacies Strengthen Communities Through Vaccination

EnlivenHealth, a subsidiary of Omnicell, announced the launch of VaxReach, a proactive vaccine outreach program designed to help pharmacies identify eligible patients and automate engagement to drive in-store traffic. Based on internal modeling, the solution has the potential to increase monthly vaccinations by up to 66% by leveraging automated patient identification and messaging. The company will highlight VaxReach at ThoughtSpot 2026 as pharmacies prepare for the respiratory and flu season.

•3mo ago

Omnicell Announces Second Quarter 2026 Financial Results

Omnicell reported second quarter 2026 revenue of $312 million, up 7% year-over-year, driven by growth in connected devices and SaaS offerings. GAAP net income rose to $24 million, or $0.52 per diluted share, compared to $6 million in the prior year, aided by a $15 million tariff refund. Management raised its full-year 2026 outlook, increasing non-GAAP EBITDA guidance to a range of $175 million to $185 million and non-GAAP EPS to $2.15 to $2.30. The company also tightened its full-year revenue guidance to $1.225 billion to $1.245 billion. Operationally, the company appointed Nnamdi Njoku as President and COO and added two new executive roles to support long-term growth in pharmacy and specialty services.

•3mo ago

Nnamdi Njoku Appointed President of Omnicell

Nnamdi Njoku has been appointed President of Omnicell, effective July 1, 2026, while retaining his role as Chief Operating Officer. Randall Lipps continues to serve as Chief Executive Officer and Chairman, allowing him to focus on strategic collaborations and the long-term evolution of the solution portfolio. Mr. Njoku brings over 18 years of experience from Medtronic, where he led a $2 billion operating unit, and will now oversee global operations and the company's AI platform strategy.

•4mo ago

Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business

Omnicell appointed Dan Mandoli as Senior Vice President and General Manager of its Specialty Pharmacy Services business. Mandoli brings over 30 years of healthcare leadership experience, most recently serving as COO at Altruix and previously leading specialty pharmacy operations at Elevance Health and Express Scripts. The company views specialty pharmacy and 340B services as key growth drivers, citing Mandoli’s track record in scaling these businesses as critical to expanding value for health systems.

•5mo ago

Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer

Omnicell appointed Rick Couldry as Senior Vice President and Chief Pharmacy and Clinical Officer, a newly created role designed to integrate health system pharmacy perspectives into the company’s innovation roadmap and portfolio decisions. Couldry brings 30 years of hospital pharmacy leadership experience from his previous tenure as Vice President of Pharmacy at The University of Kansas Health System. The strategic hire aims to ensure Omnicell’s solutions address real-world clinical needs, strengthening the company’s position as a partner to pharmacy leaders.

•6mo ago

Omnicell Announces First Quarter 2026 Financial Results

Omnicell reported Q1 2026 revenue of $310 million, up 15% year-over-year, with GAAP net income of $11 million compared to a loss of $7 million in the prior year. Driven by strong profitability and cost discipline, the company raised its full-year 2026 non-GAAP EBITDA guidance to $153M-$168M and non-GAAP EPS to $1.80-$2.00. Operational cash flow doubled to $55 million, while customer engagement is underway for the new Omnicell Titan XT and OmniSphere platforms.

•6mo ago